blog
For many people living with severe eczema, Dupixent feels like a breakthrough.
After years of painful flare-ups, constant itching, and treatments that never seemed to last, the medication can finally bring relief. Skin calms down. Redness fades. Sleep improves. Life feels manageable again.
But for some patients, that improvement may hide something more serious.
Doctors and researchers have raised concerns about what’s being called the “masking effect” — a situation where Dupixent improves the appearance of eczema while an underlying condition, Cutaneous T-Cell Lymphoma (CTCL), continues to develop. Understanding this issue could make a critical difference to early diagnosis and treatment.
At Morris James, we help people harmed by Dupixent seek accountability from drug manufacturers for failing to properly warn patients and doctors about these potential risks.
CTCL is a rare type of non-Hodgkin lymphoma that begins in certain white blood cells called T-cells. Instead of protecting the body, these abnormal T-cells attack the skin.
In its early stages — especially a form called mycosis fungoides — CTCL can look almost identical to stubborn eczema. Patients may notice:
Because the symptoms overlap so closely, CTCL is often misdiagnosed as eczema even without Dupixent. When Dupixent enters the picture, things can become even more complicated.
Dupixent (dupilumab) works by blocking two inflammatory proteins in the immune system: IL-4 and IL-13. These proteins play a major role in eczema symptoms. By reducing inflammation, Dupixent can significantly improve the visible signs of eczema.
Here’s where the concern arises.
If a patient actually has early-stage CTCL — but it is mistaken for eczema — Dupixent may calm the inflammation without stopping the abnormal cancerous T-cells from multiplying. The skin may look better temporarily, even while the lymphoma progresses underneath.
One way to think about it: it’s like turning off a smoke alarm without putting out the fire. The noise stops. The room feels calmer. But the problem may still be there.
Because the skin appears improved, providers may delay ordering a biopsy. That delay matters.
CTCL can be difficult to diagnose early. It sometimes takes multiple doctor visits and tests to confirm. However, there are warning signs that deserve closer attention, especially for patients using Dupixent.
If you are experiencing any of the below signs or are concerned about any other symptoms, you should consult your healthcare provider as soon as possible:
In more advanced cases, CTCL can develop into Sézary Syndrome, which affects the blood and lymph nodes and is more aggressive.
These symptoms do not automatically mean cancer. But they do mean that a consultation with your medical provider is necessary.
Early-stage CTCL is often managed with skin-directed treatments and careful monitoring. When caught early, patients may have more treatment options and better long-term control. According to the National Cancer Institute, a patient’s prognosis is based on the extent of the disease at presentation. When diagnosis is delayed, the disease may progress which can require systemic therapies and carry a more serious prognosis.
That is why a delayed diagnosis of CTCL caused by Dupixent causes concern in medical and legal circles.
Patients and physicians need to know the risks of taking a medication so they can make informed choices and monitor for those risks. When drug manufacturers withhold that information, they manufacturers should be liable for the harm they cause.
Our firm is reviewing cases involving patients who:
In product liability cases, one key issue is whether a medication manufacturer adequately warned patients and doctors about known or emerging risks. If a drug’s effects may interfere with timely diagnosis of cancer, that warning can be critically important.
Every case is unique. But individuals diagnosed with CTCL after using Dupixent may have the right to pursue compensation for:
We handle these cases on a contingency fee basis. That means there are no attorney’s fees unless we obtain compensation for you.
Learn more about who qualifies to file a Dupixent lymphoma lawsuit.
Dupixent has helped many people regain control of severe eczema. That relief is real and meaningful. But patients and physicians need to know that they should be on alert for masked symptoms of more serious disease.
If you or a loved one developed Cutaneous T-Cell Lymphoma after using Dupixent — or if you experienced months of worsening symptoms before receiving a diagnosis — you deserve answers.
We are here to listen. We offer a free, confidential consultation to review your situation and explain your options clearly and honestly.
Call 302.655.2599 or contact us online today by submitting the form below.
When your health is at stake, answers matter.
Article co-authored by Matthew Fogg and Keith Donovan, mass tort and personal injury attorneys representing individuals harmed by Dupixent.
